Liu Yongjun

Responsible for the group's global R&D, product pipeline strategy, business cooperation and international business, etc. Dr. Liu received his doctorate in internal medicine from Bethune Medical University in 1984, and his doctorate in immunology from the University of Birmingham School of Medicine in 1989, and completed his postdoctoral program training at the university two years later.

Dr. Liu has been deeply involved in the biomedical industry for more than 30 years. He is a world-renowned scientist in the fields of immunology, oncology and translational medicine. He has extensive work experience in internationally renowned scientific research institutions and R&D departments of the world's top pharmaceutical companies. In 1991, Dr. Liu joined French multinational pharmaceutical company Schering-Plough Lyon as a senior scientist. In 1997, he joined Schering-Plough's U.S. biotechnology company DNAX Institute as chief scientist. In 2002, Dr. Liu was hired by the University of Texas MD Anderson Cancer Center (UT MD Anderson Cancer Center) as the Vivian Smith Distinguished Chair Professor, head of the Department of Immunology and founding director of the Center for Cancer Immunology Research (CCIR). In 2011, Dr. Liu was hired by the Baylor Institute as Chief Scientific Officer and Director of the Baylor Institute for Immunology. After working in academia for more than 10 years, Dr. Liu was hired by AstraZeneca's global biopharmaceutical subsidiary Medimmune in 2014 as Chief Scientific Officer and Global Head of Research. Prior to joining Innovent, Dr. Liu served as the global head of research at Sanofi from 2016 to 2020.

Dr. Liu has rich scientific research results and experience in scientific research institutions. He has published more than 260 papers in top academic journals such as Nature and Science, with a total of more than 94,000 citations. These studies have provided multiple key drug targets for the fields of immunology and oncology, such as thymic stromal lymphopoietin (TSLP), OX40 (CD134), plasmacytoid dendritic cells (pDC), etc., promoting multiple fields Advanced preclinical research has enabled many candidate drugs to move from initial laboratory discovery to clinical practice, benefiting patients.